---
schema_version: "secwatch.filing_event.v1"
accession: "0001671927-26-000020"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2026-08-06T11:01:22+00:00"
generated_at: "2026-08-06T11:06:13.085298+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunocore Q2 2026: KIMMTRAK rev $115.9M (+18% YoY); net loss $0.8M; TEBE-AM enrollment nearing target

## Summary
- KIMMTRAK net revenue $115.9M in Q2 2026, up 18% YoY; US sales $74.9M, Europe $34.1M, international $6.9M.
- Net loss narrowed to $0.8M ($0.02 loss per share) from $10.3M loss in Q2 2025; H1 2026 net income $12.2M.
- Phase 3 TEBE-AM trial for 2L+ advanced cutaneous melanoma enrollment nearing 540 patients; topline data possible end of 2026.
- Five-year OS data: KIMMTRAK OS rate 16% vs 8% control; median OS 21.6 vs 16.9 months (HR 0.67).
- Brenetafusp monotherapy in heavily pretreated advanced melanoma: ORR 17%, DCR 67% at 160 mcg; supports Phase 3 PRISM-MEL-301 dose.

## SEC filing metadata
- accession: 0001671927-26-000020
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2026-08-06T11:01:22+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000167192726000020/0001671927-26-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000167192726000020/imcr-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001671927-26-000020
- JSON: https://secwatch.observer/filing/0001671927-26-000020.json
- Plain text: https://secwatch.observer/filing/0001671927-26-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.